CASE STUDY

Elucidata x Hookipa: 7x Faster Insights In Translational Research

Key Highlights

  • Hookipa Pharmaceuticals is a Boston-based clinical-stage therapeutics company focused on developing developing cancer and infectious disease therapeutics.
  • They wanted to analyze clinical assay data for translational research. However, as data was sourced from multiple vendors it was unharmonized and voluminous. This analysis and management of data laborious and resource-intensive.
  • To address these challenges, Elucidata developed an end-to-end solution to harmonize metadata across all molecular and clinical data-types, integrate patient metadata with assay data and build a custom dashboard for visualizing data across multiple patients and assays.
  • By leveraging Polly, scientists could accelerate time to analysis by 7X, from one week to one day, save more than 1000 hours on manual data curation and enhance to quality of translational research to support outcomes like patient stratification.

All Case Studies

Case study: Accelerated Target ID using ML-Ready data on Polly

Elucidata Transforms RNAi Drug Discovery: 2X Faster Gene ID & Cell Annotation

Read More
Case study: Accelerated Target ID using ML-Ready data on Polly

Elucidata x Hookipa: 7x Faster Insights In Translational Research

Read More
Case study: Accelerated Target ID using ML-Ready data on Polly

Optimizing Diagnostics: Elucidata Doubles (2X) Sample to Report Speed

Read More
Case study: Accelerated Target ID using ML-Ready data on Polly

Accelerating Immune Disorder Research with 5M Harmonized Cells

Read More
Case study: Accelerated Target ID using ML-Ready data on Polly

Elucidata x Celsius: 4x Faster Insights with Single-cell Infra

Read More
Case study: Accelerated Target ID using ML-Ready data on Polly

Polly Delivers STAR Quality Data at High Throughput, 5x Lower Cost

Read More
Request Demo